Alphamab's cancer cash

Alphamab Oncology to push several programs through the clinic with $100M A round

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing.

Investors in the round, which closed on Nov. 17, include Advantech

Read the full 396 word article

User Sign In